ICICI Prudential Life Insurance Ltd.



Result Update – Q4 FY22

II 19th April 2022

Page 2

ICICI Prudential Life Insurance Ltd.

VNB margins continues to expand; overall persistency improves

CMP	Target	Potential Upside	Market Cap (INR Mn)	Recommendation	Sector
INR 542	INR 772	42.4%	INR 7,83,332	BUY	Life Insurance


Result Highlights of Q4FY22 & FY22:


- In Q4FY22, the GWP grew 25.8% QoQ while declining 3.2% YoY on last year's high base. For the full year FY22, the GWP grew by 4.8% YoY due to improved growth traction in New Business Premium (NBP).
- The VNB for FY22 grew by 33.4% YoY to INR 21.63 bn. The VNB margin for FY22 stood at 28.0%, up from 25.1% for FY21. This was led by a robust growth of 20% in APE. In Q4FY22, VNB margins stood at 29.7% vs 23.6% in Q4FY21.
- The solvency ratio was 204.5% against the regulatory requirement of 150%. The total assets under management of the company were INR 2,404.92 bn as on March 31, 2022, a growth of 12.3% over INR 2,142.18 bn as on March 31, 2021.

MARKET DATA

Shares outs (Mn)	1,437
Equity Cap (INR Mn)	91,631
Mkt Cap (INR Mn)	7,83,332
52 Wk H/L (INR)	724/430
Volume Avg (3m K)	1,797
Face Value (INR)	10
Bloomberg Code	IPRU: IN

SHARE PRICE PERFORMANCE





MARKET INFO

SENSEX	57,167
NIFTY	17,174

KEY FINANCIALS

Particulars (INR Mn)	FY20	FY21	FY22	FY23E	FY24E
GWP	3,34,307	3,57,328	3,74,580	4,16,889	4,74,291
PAT	10,685	9,601	7,541	12,385	13,314
EPS (INR/Share)	7.4	6.7	5.2	8.6	9.2
NBP-APE	73,810	59,911	77,330	83,221	1,00,098
VNB	16,050	16,210	21,630	23,718	29,028
VNB Margin (%)	21.8%	21.8%	28.0%	28.5%	29.0%
EVPS (INR/Share)	160.4	202.7	218.7	260.2	308.2

Source: Company, KRChoksey Research

Strong APE growth reported on a sequential basis: IPRU reported a strong APE growth of 35.2% QoQ while 4.0% YoY in Q4FY22. The protection APE for the quarter saw a strong growth of 32.8% YoY, contributing 17.5% to the total product portfolio. New business premium de-grew by 5.4% YoY at INR 49,076 Mn in Q4FY22. The company continued to focus on its well-diversified product mix with linked savings at 48%, traditional savings at 28%, protection at 17%, and a balance of 7% for FY22. The annuity New Business Premium (NBP) grew by 29% YoY, while the protection NBP segment grew 35% YoY in FY22. The company believes that these segments are underpenetrated in India and offer a tremendous growth opportunity. The new business sum assured stood at INR 77,31,460 Mn for FY22, making IPRU the market leader. This was aided by IPRU's innovative product pipeline & vast distribution network. The management is optimistic about the long-term structural play for the Protection business and believes that retail protection, which has a high-rated profit segment, will see a strong recovery in upcoming quarters. The company's market share climbed to 13.4% for 11MFY22, up from 12.5% in FY21, maintaining its private sector market leadership.

Expansion of VNB margins strong with outlook intact: The VNB for Q4FY22 grew by 31.1% YoY to INR 7,750 Mn, with the VNB margin for Q4FY22 at 29.7%, an improvement of 302 bps/615bps QoQ/YoY, respectively with improvement in the Annuity and Protection business contribution and overall healthy growth in APE. The management maintains its guidance of doubling the VNB by FY23E driven by a robust business model, innovative & diverse & high margin product offerings, coupled with a diverse distribution mix.

Persistency improves; expenses slightly higher: IPRU continues to see improvements in the 13th and 61st-month persistency ratios. The 13th-month persistency ratio has improved by 90 bps YoY to 85.7% at the end of March-22. Similarly, its 61st-month persistency ratio has improved to 54.4% at the end of March-21, an improvement of 170 bps QoQ. The company reported higher operating expenses in Q4FY22 due to higher discretionary expenses considering the pandemic's easing and investment in capacity for future growth.

SHARE HOLDING PATTERN (%)

Particulars	Mar-22	Dec-21	Sep-21
Promoters	73.4	73.4	73.4
FIIs	16.4	16.9	17.2
DIIs	4.7	4.3	4.1
Others	5.5	5.4	5.3
Total	100.0	100.0	100.0

10%

GWP CAGR between FY21 and FY24E

21%

VNB CAGR between FY21 and FY24E

Result Update – Q4 FY22

II 19th April 2022

Page 3


ICICI Prudential Life Insurance Ltd.

Key Concall Highlights:

- The rate of high infection due to Omicron virus in the month of Jan-Feb'22, the company had to face some loss in terms of
 productivity.
- IPRU's focus areas for upcoming quarters will be a revival of the retail protection business, which is currently showing subdued growth and expanding its annuity business further by increasing the contribution.
- The company is well focused on its 4P strategy, leading to a substantial expansion in VNB margins and the aspiration to double the VNB by FY23E.
- Protection remains a long-term growth story for the industry.
- The company has achieved partnerships with 27 banks as of 31st March 2022 and is performing well for the company. The non-ICICI contribution has increased for IPRU from 4% in FY19 to 14% in FY22.
- ICICI bank reported subdued growth in APE due to a slow down in the retail protection segment. The management expects this
 to turn around for a select set of products in the upcoming months.
- IPRU has taken a minimum price hike in the retail protection segment, which has not impacted the business.
- The retail protection segment is expected to trigger VNB's margin expansion in FY23E.
- The company is expected to focus on increasing the contribution from the agency & direct segments to attain the growth opportunities.
- IPRU continued to invest in new digital initiatives and adding employees, which has led to higher cost ratios for FY22. However, this increase is not expected to continue in FY23E. According to the management, the share from ULIP has fallen sharply in FY22, which has led to a well-diversified mix.


Valuation and view

IPRU in Q4FY22 has shown a healthy performance on margin & APE front. The company's increasing focus on the Annuity & Protection segment has helped IPRU to deliver higher margins of 29.7% in Q4FY22. In addition, this expansion will support attaining its objective of doubling its VNB by FY23E. IPRU continues to improve its market share every quarter, which is better than its peers. Thus, we believe IPRU is well-positioned to grab the upcoming growth opportunity in the long-term structural story. We expect GWP to grow at a CAGR of 10% over FY21-24E and margins at ~29.0% with increased contribution from the high-margin product segment & improving its customer base using new distribution partnerships. Since our last update, the ICICI Prudential Life Insurance share has corrected by ~6%. We assign a 2.5x P/EV on FY24E EVPS of INR 310 and a VNB multiple of 31x to arrive at a weighted average Target Price (unchanged) of INR 772 per share (50:50 weights on the P/EV and appraisal value methodology); indicating a 42.4% upside from the CMP. Accordingly, we re-iterate our "BUY" rating on the shares of ICICI Prudential Life Insurance Ltd.







Channel mix on APE basis (%)



Product mix on APE basis (%)



Value of new business



Source: Company, KRChoksey Research

Result Update – Q4 FY22

II 19th April 2022

Page 4

ICICI Prudential Life Insurance Ltd.

KEY FINANCIALS

Exhibit 1: Revenue Account/Policy Holder's Account

Particulars (INR Mn)	FY20	FY21	FY22	FY23E	FY24E
Gross premiums	3,34,307	3,57,328	3,74,580	4,16,889	4,74,291
Reinsurance ceded	5,520	7,595	11,367	8,338	9,486
Net premiums	3,28,787	3,49,734	3,63,213	4,08,551	4,64,806
Net income from investments	-1,09,395	4,91,057	2,72,432	2,05,982	2,29,580
Total income	2,19,393	8,40,791	6,35,645	6,14,533	6,94,385
Commission expenses	15,860	15,002	16,729	24,180	27,509
Operating expenses	28,469	26,883	36,730	47,942	54,544
Service tax on linked charges	6,534	6,546	6,914	7,593	8,136
Other expenses/provisions	19	238	281	250	250
Operating profit	1,68,511	7,92,122	5,74,991	5,34,567	6,03,947
Benefits paid (net)	1,94,506	2,26,409	2,93,588	2,09,237	2,37,927
Interim Bonuses Paid	2,132	0	0	О	0
Change in reserves	-50,569	5,43,241	2,57,838	2,97,237	3,35,878
Provisions	1,314	1,418	1,662	2,528	2,713
Surplus/(Deficit) After Tax	21,128	21,054	21,904	25,565	27,429

Source: Company, KRChoksey Research

Exhibit 2: Premium Schedule

Particulars (INR Mn)	FY20	FY21	FY22	FY23E	FY24E
First year premiums	65,078	51,872	59,655	71,586	85,903
Single premiums	59,797	80,389	95,367	1,16,348	1,41,945
New business premium (NBP)	1,24,875	1,32,261	1,55,023	1,87,934	2,27,848
NBP growth (%)	20%	6%	17%	21%	21%
Renewal premiums	2,09,432	2,25,068	2,19,558	2,28,954	2,46,443
Renewal premiums growth (%)	2%	7%	-2%	4%	8%
Total premiums	3,34,307	3,57,328	3,74,580	4,16,889	4,74,291
Total premium growth (%)	8%	7%	5%	11%	14%
NBP – APE	73,810	59,911	77,330	83,221	1,00,098
NBP - APE growth (%)	-5%	-19%	29%	8%	20%

Source: Company, KRChoksey Research

Exhibit 3: Profit & Loss Account/Shareholder's Account

Particulars (INR Mn)	FY20	FY21	FY22	FY23E	FY24E
Transfer from Technical account	19,885	19,849	21,602	25,065	26,679
Income from investments & other income	6,600	7,690	10,136	8,278	9,107
Total income	26,485	27,538	31,738	33,342	35,786
Total expenses	15,799	16,724	23,833	20,305	21,772
PBT	10,685	10,814	7,906	13,037	14,014
Provision for tax	0	1,213	365	652	701
PAT	10,685	9,601	7,541	12,385	13,314

Source: Company, KRChoksey Research

Result Update – Q4 FY22

II 19th April 2022

Page 5

ICICI Prudential Life Insurance Ltd.

Exhibit 4: Balance Sheet

Particulars (INR Mn)	FY20	FY21	FY22	FY23E	FY24E
Sources of funds					
Share capital	14,358	14,360	14,373	14,373	14,373
Reserves and surplus	61,056	70,671	75,915	85,213	95,208
Fair value change account - net	-3,228	6,158	1,342	1,342	1,342
Shareholders' fund	72,185	91,189	91,631	1,00,928	1,10,923
Liabilities (Policyholder's Funds)					
Fair value change account - net	-2,525	29,935	28,275	31,842	35,982
Revaluation reserve-Investment property	656	687	680	765	865
Policy liabilities	4,73,556	6,02,156	7,36,822	8,29,790	9,37,663
Provision for linked liabilities	9,89,764	10,58,551	11,61,143	13,07,650	14,77,645
Credit/[debit] fair value change account	-1,09,397	2,19,153	2,44,271	2,75,092	3,10,854
Discontinued due to non-payment of premium	90,482	1,07,787	1,03,249	1,16,276	1,31,392
Sub-Total	14,42,537	20,18,269	22,74,439	25,61,417	28,94,401
Funds for future Appropriations	12,327	13,540	13,833	14,500	14,500
Total Sources of Funds	15,27,049	21,35,003	23,91,903	26,99,104	30,44,977
Application of Funds					
Investments					
- Shareholders	74,209	1,00,902	98,535	1,08,406	1,19,265
- Policyholders	4,67,503	6,35,726	7,73,880	8,51,268	9,36,395
Asset held to cover linked liabilities	9,70,850	13,85,491	15,08,663	16,59,529	18,25,482
Loans	4,631	6,628	9,401	10,000	10,000
Fixed assets - net block	4,776	4,572	4,872	4,756	4,756
Deferred tax asset	0	0	0	0	0
Net current assets	5,080	1,684	-3,449	65,145	1,49,078
Total Applications of Funds	15,27,049	21,35,003	23,91,903	26,99,104	30,44,977

Source: Company, KRChoksey Research

Exhibit 5: EV Calculation

Particulars (INR Mn)	FY20	FY21	FY22	FY23E	FY24E
Opening EV	2,16,230	2,30,300	2,91,060	3,16,250	3,76,221
Unwind	17,250	16,610	20,850	22,770	27,088
VNB (or NBAP)	16,050	16,210	21,630	23,718	29,028
Operating variance	-410	2,240	-10,560	6,570	6,570
EV Operating Profit (EVOP)	32,890	35,060	31,920	53,058	62,686
Non-operating variance	-14,760	25,670	-4,370	10,000	10,000
EV Profit	18,130	60,730	27,550	63,058	72,686
Net capital injection	-4,050	30	-2,360	-3,087	-3,319
Closing EV	2,30,310	2,91,060	3,16,250	3,76,221	4,45,588

Source: Company, KRChoksey Research

Exhibit 6: Key Financials

Particulars (INR Mn)	FY20	FY21	FY22	FY23E	FY24E
Total premium	3,34,307	3,57,328	3,74,580	4,16,889	4,74,291
Net premium earned	3,28,787	3,49,734	3,63,213	4,08,551	4,64,806
NBP-APE	73,810	59,911	77,330	83,221	1,00,098
Combined ratio (%)	13.3%	11.4%	14.3%	17.3%	17.3%
Surplus/(Deficit)	21,128	21,054	21,904	25,565	27,429
VNB margin (%)	21.8%	21.8%	28.0%	28.5%	29.0%
PAT	10,685	9,601	7,541	12,385	13,314
EPS (Rs.)	7.4	6.7	5.2	8.6	9.3
EVPS (Rs.)	160.4	202.7	220.0	261.8	310.0
RoEV (%)	15.2%	15.2%	11.0%	16.8%	16.7%
RoE (%)	15.0%	11.8%	8.2%	12.9%	12.6%

Source: Company, KRChoksey Research

Result Update - Q4 FY22

II 19th April 2022

Page 6

ICICI Prudential Life Insurance Ltd.

ICICI PruLife I	ICICI PruLife Insurance			Rating Legend (Expected over a 12-month period)		
Date	CMP (INR)	TP (INR)	Recommendation	Our Rating	Upside	
19-Apr-22	542	772	BUY	Buy	More than 15%	
19-Jan-22	574	772	BUY		Wiere triair 15%	
20-Oct-21	636	772	BUY	Accumulate	5% – 15%	
31-Aug-21	660	679	HOLD	Hold	0 – 5%	
20-Apr-21	477	526	ACCUMULATE	Dadusa	F9/ 0	
17-Mar-21	444	526	BUY	Reduce	-5% – 0	
15-Dec-20	499	526	ACCUMULATE	Sell	Less than – 5%	

ANALYST CERTIFICATION:

I, Vikrant Kashyap (PGDBM-Finance & IT), Research Analyst, author and the name subscribed to this report, hereby certify that all of the views expressed in this research report accurately reflect my views about the subject issuer(s) or securities. I also certify that no part of our compensation was, is, or will be directly or indirectly related to the specific recommendation(s) or view(s) in this report.

Terms & Conditions and other disclosures:

KRChoksey Shares and Securities Pvt. Ltd (hereinafter referred to as KRCSSPL) is a registered member of National Stock Exchange of India Limited and Bombay Stock Exchange Limited. KRCSSPL is a registered Research Entity vides SEBI Registration No. INH000001295 under SEBI (Research Analyst) Regulations, 2014.

We submit that no material disciplinary action has been taken on KRCSSPL and its associates (Group Companies) by any Regulatory Authority impacting Equity Research Analysis activities.

KRCSSPL prohibits its analysts, persons reporting to analysts and their relatives from maintaining a financial interest in the securities or derivatives of any companies that the analyst covers. The information and opinions in this report have been prepared by KRCSSPL and are subject to change without any notice. The report and information contained herein is strictly confidential and meant solely for the selected recipient and may not be altered in any way, transmitted to, copied or distributed, in part or in whole, to any other person or to the media or reproduced in any form, without prior written consent of KRCSSPL. While we would endeavor to update the information herein on a reasonable basis, KRCSSPL is not under any obligation to update the information. Also, there may be regulatory, compliance or other reasons that may prevent KRCSSPL from doing so. Non-rated securities indicate that rating on a particular security has been suspended temporarily and such suspension is in compliance with applicable regulations and/or KRCSSPL policies, in circumstances where KRCSSPL might be acting in an advisory capacity to this company, or in certain other circumstances.

This report is based on information obtained from public sources and sources believed to be reliable, but no independent verification has been made nor is its accuracy or completeness guaranteed. This report and information herein is solely for informational purpose and shall not be used or considered as an offer document or solicitation of offer to buy or sell or subscribe of or securities or other financial instruments. Though disseminated to all the customers simultaneously, not all customers may receive this report at the same time. KRCSSPL will not treat recipients as customers by virtue of their receiving this report. Nothing in this report constitutes investment, legal, accounting and tax advice or a representation that any investment or strategy is suitable or appropriate to your specific circumstances. The securities discussed and opinions expressed in this report may not be suitable for all investors, who must make their own investment decisions, based on their own investment objectives, financial positions and needs of specific recipient. This may not be taken in substitution for the exercise of independent judgment by any recipient. The recipient should independently evaluate the investment risks. The value and return on investment may vary because of changes in interest rates, foreign exchange rates or any other reason. KRCSSPL accepts no liabilities whatsoever for any loss or damage of any kind arising out of the use of this report. Past performance is not necessarily a guide to future performance. Investors are advised to see Risk Disclosure Document to understand the risks associated before investing in the securities markets. Actual results may differ materially from those set forth in projections. Forward-looking statements are not predictions and may be subject to change without notice. Our employees in sales and marketing team, dealers and other professionals may provide oral or written market commentary or trading strategies that reflect opinions that are contrary to the opinions expressed herein, .In reviewing these materials, you should be aware that any or all of the foregoing, among other things, may give rise to real or potential conflicts of interest.

Associates (Group Companies) of KRCSSPL might have received any commission/compensation from the companies mentioned in the report during the period preceding twelve months from the date of this report for services in respect of brokerage services or specific transaction or for products and services other than brokerage services.

KRCSSPL or its Associates (Group Companies) have not managed or co-managed public offering of securities for the subject company in the past twelve months.

KRCSSPL encourages the practice of giving independent opinion in research report preparation by the analyst and thus strives to minimize the conflict in preparation of research report. KRCSSPL or its analysts did not receive any compensation or other benefits from the companies mentioned in the report or third party in connection with preparation of the research report. Accordingly, neither KRCSSPL nor Research Analysts have any material conflict of interest at the time of publication of this report.

It is confirmed that, Vikrant Kashyap (PGDBM-Finance & IT), Research Analyst of this report have not received any compensation from the companies mentioned in the report in the preceding twelve months. Compensation of our Research Analysts is not based on any specific brokerage service transactions.

KRCSSPL or its associates (Group Companies) collectively or its research analyst do not hold any financial interest/beneficial ownership of more than 1% (at the end of the month immediately preceding the date of publication of the research report) in the company covered by Analyst, and has not been engaged in market making activity of the company covered by research

It is confirmed that, Vikrant Kashyap (PGDBM-Finance & IT), Research Analyst do not serve as an officer, director or employee of the companies mentioned in the report.

This report is not directed or intended for distribution to, or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other Jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject KRCSSPL and affiliates to any registration or licensing requirement within such jurisdiction. The securities described herein may or may not be eligible for sale in all jurisdictions or to certain category of investors. Persons in whose possession this document may come are required to inform them of and to observe such restriction.

Please send your feedback to research.insti@krchoksey.com Visit us at www.krchoksey.com KRChoksey Shares and Securities Pvt. Ltd Registered Office:

1102, Stock Exchange Tower, Dalal Street, Fort, Mumbai – 400 001. Phone: +91-22-6633 5000; Fax: +91-22-6633 8060. **Corporate Office:**

ABHISHEK, 5th Floor, Link Road, Andheri (W), Mumbai – 400 053. Phone: +91-22-6696 5555; Fax: +91-22-6691 9576.

Thomson Reuters, Factset and Capital IQ